Neonatal hair analysis by liquid chromatography-high-resolution mass spectrometry to reveal gestational exposure to venlafaxine

Therapeutic Drug Monitoring

Volumn 32, Issue 1, 2010, Pages 30-39

  Favretto, Donata ^a   Stocchero, Giulia ^a   Vogliardi, Susanna ^a   Frison, Giampietro ^a   Trevisanuto, Daniele ^a   Castagna, Franca ^a   Ferrara, Santo Davide ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Hair analysis; Mass spectrometry; Therapeutic drug monitoring; Venlafaxine

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; DESVENLAFAXINE; DIDESMETHYLVENLAFAXINE; DRUG DERIVATIVE; ERGOTAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORDAZEPAM; OPIATE DERIVATIVE; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; CARDIOTOXICITY; DRUG HAIR LEVEL; DRUG MONITORING; ELECTROSPRAY; FEMALE; GASTROINTESTINAL TOXICITY; GESTATION PERIOD; HAIR ANALYSIS; HUMAN; HUMAN EXPERIMENT; INFANT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NEWBORN; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; VALIDATION STUDY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANOLS; DRUG MONITORING; FEMALE; HAIR; HUMANS; INFANT; INFANT, NEWBORN; PREGNANCY; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TWINS, MONOZYGOTIC;

EID: 75649131835     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181c01e16     Document Type: Article

References (54)

1. Muth EA, Haskins JT, Moyer JA, et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol. 1986;35:4493-4497.
2. Muth EA, Haskins JT, Moyer JA, et al. An eight-week, open-label, uncontrolled, multicenter, Phase IV study of remission rates in outpatients and inpatients with major depression treated with venlafaxine. Drug Dev Res. 1991;23:191199.
3. Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther. 2002;24: 1194-1200.
4. De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol. 2002;5:115-120.
5. Mandrioli R, Mercolini L, Cesta R, et al. Analysis of the second generation antidepressant venlafaxine and its main active metabolite O-desmethylvenlafaxine in human plasma by HPLC with spectrofluori-metric detection. Chromatogr B Analyt Technol Biomed Life Sci. 2007; 856:88-94.
6. Charlier C, Pinto E, Ansseau M, et al. Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients. J Psychopharmacol. 2002;16:369-372.
7. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet. 1995;29:10-18.
8. Hicks DR, Wolaniuk D, Russell A, et al. A high-performance liquid chromatographic method for the simultaneous determination of venlafax-ine and O-desmethylvenlafaxine in biological fluids Ther Drug Monit. 1994;16:100-107.
9. Sweetman SC, Ed. Martindale The Complete Drug Reference. 34th ed. London, UK: Pharmaceutical Press; 2005.
10. Long C, Crifasi J, Maginn D, et al. Comparison of analytical methods in the determination of two venlafaxine fatalities. J Anal Toxicol. 1997;21: 166-169.
11. DeVane CL, Stowe ZN, Donovan JL, et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol. 2006;20:54-59.
12. Hostetter A, Ritchie JC, Stowe ZN. Amniotic fluid and umbilical cord blood concentrations of antidepressants in three women. Biol Psychiatry. 2000;48:1032-1034.
13. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001;158:1728-1730.
14. de Moor RA, Mourad L, ter Haar J, et al. Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy. Ned Tijdschr Geneeskd. 2003 28:1370-1372.
15. Kintz P, Tracqui A, Mangin P. Tobacco, drug and narcotic abuse during pregnancy. Evaluation of in utero exposure by analysis of hair of the neonate. Presse Med. 1992;21:2139-2141.
16. Bar-Oz B, Klein J, Karaskov T, et al. Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse. Arch Dis Child Fetal Neonatal Ed. 2003;88:98-100.
17. Frison G, Favretto D, Vogliardi S, et al. Quantification of citalopram or escitalopram and their demethylated metabolites in neonatal hair samples by liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2008;30:467-473.
18. Frison G, Favretto D, Tedeschi L, et al. Detection of thiopental and pentobarbital in head and pubic hair in a case of drug-facilitated sexual assault. Forensic Sci Int. 2003;133:171-174.
19. Favretto D, Frison G, Vogliardi S, et al. Potentials of ion trap collisional spectrometry for liquid chromatography/electrospray ionization tandem mass spectrometry determination of buprenorphine and nor-buprenor-phine in urine, blood and hair samples. Rapid Commun Mass Spectrom. 2006;20:1257-1265.
20. Favretto D, Frison G, Vogliardi S, et al. Highly specific quantification of ergotamine in urine, blood, and hair samples by liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2007;29:325-332.
21. Vu RL, Helmeste D, Albersa L, et al. Rapid determination of venlafaxine and O-desmethylvenlafaxine in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr B Biomed Appl. 1997;703:195-201.
22. Waschgler R, Moll W, König P, et al. Quantification of venlafaxine and O-desmethylvenlafaxine in human serum using HPLC analysis. Int J Clin Pharmacol Ther. 2004;42:724-728.
23. Raut BB, Kolte BL, Deo AA, et al. A rapid and sensitive HPLC method for the determination of venlafaxine and o-desmethylvenlafaxine in human plasma with UV detection. J Liq Chromatogr Relat Technol. 2003; 26:1297-1313.
24. Duverneuil, C, de la Grandmaison GL, de Mazancourt P, et al. A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepres-sant drugs. Ther Drug Monit. 2003;25:565-573.
25. Clement EM, Odontiadis J, Franklin M. Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction. J Chromatogr B Biomed Sci Appl. 1998;705:303-308.
26. Bhatt J, Jangid A, Venkatesh G, et al. Liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for simultaneous determination of venlafaxine and its active metabolite O-desmethyl venlafaxine in human plasma. J Chromatogr B. 2005;829:75-81.
27. Castaing N, Titier K, Receveur-Daurel M, et al. Quantification of eight new antidepressants and five of their active metabolites in whole blood by high-performance liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2007;31:334-341.
28. Liu W, Cai HL, Li HD. High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma. J Chromatogr. 2007;850:405-411.
29. Theron HB, van der Merwe MJ, Swart KJ, et al. Employing atmospheric pressure photoionization in liquid chromatography/tandem mass spectro-metry to minimize ion suppression and matrix effects for the quantification of venlafaxine and O-desmethylvenlafaxine. Rapid Commun Mass Spectrom. 2007;21:1680-1686.
30. de Castro A, Concheiro M, Quintela O, et al. LC-MS/MS method for the determination of nine antidepressants and some of their main metabolites in oral fluid and plasma. Study of correlation between venlafaxine concentrations in both matrices. J Pharm Biomed Anal. 2008;48:183-193.
31. Patel BN, Sharma N, Sanyal M, et al. Liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ven-lafaxine and O-desmethylvenlafaxine in human plasma and its application to a bioequivalence study. J Pharm Biomed Anal. 2008;47:603-611.
32. Bickeboeller FJ, Maurer HH. Screening for detection of new anti-depressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. Ther Drug Monit. 2001; 23:61-70.
33. Salgado-Petinal C, Lamas JP, Garcia-Jares C, et al. Rapid screening of selective serotonin re-uptake inhibitors in urine samples using solid-phase microextraction gas chromatography-mass spectrometry. Anal Bioanal Chem. 2005;382:1351-1359.
34. Allen KR. Interference by venlafaxine ingestion in the detection of tramadol by liquid chromatography linked to tandem mass spectrometry for the screening of illicit drugs in human urine. Clin Toxicol. 2006;44: 147-153.
35. Wille SM, De Letter EA, Piette MH, et al. Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry. Int J Legal Med. 2008 [Epub ahead of print].
36. Klinzig F, Vinner E, Brassart C, et al. Hair analysis by LC-MS as evidence of nalbuphine abuse by a nurse. J Anal Toxicol. 2007;31:62-65.
37. Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta. 2006;370:17-49.
38. Kronstrand R, Nyström I, Strandberg J, et al. Screening for drugs of abuse in hair with ion spray LC-MS-MS. Forensic Sci Int. 2004;145:183-190.
39. Moore C, Coulter C, Crompton K. Determination of cocaine, benzoylecgonine, cocaethylene and norcocaine in human hair using solid-phase extraction and liquid chromatography with tandem mass spectrometric detection. J Chromatogr B. 2007;859:208-212.
40. Miyaguchi H, Kakuta M, Iwata YT, et al. Development of a micro-pulverized extraction method for rapid toxicological analysis of methamphetamine in hair. J Chromatogr A. 2007;1163:43-48.
41. Miller EI, Wylie FM, Oliver JS. Simultaneous detection and quantification of amphetamines, diazepam and its metabolites, cocaine and its metabolites, and opiates in hair by LC-ESI-MS-MS using a single extraction method. J Anal Toxicol. 2008;32:457-469.
42. World Anti-Doping Agency. The World Anti-Doping Code. International Standard for Laboratories. Version 4.0, 1-57; 2004.
43. Guidance for Industry: Mass Spectrometry for Confirmation of the Identity of Animal Drug Residues, Federal Register 68 (92) 25617. Rockville, MD: U.S. Food and Drug Administration; 2003.
44. Tang L, Kebarle P. Dependence of ion intensity in electrospray mass spectrometry on the concentration of the analytes in the electrosprayed solution. Anal Chem. 1993;65:3654-3668.
45. Enke CG. A Predictive model for matrix and analyte effects in electrospray ionization of singly-charged ionic analytes. Anal Chem. 1997;69:4885-4893.
46. Van Loco J, Beernaert H. An alternate method validation strategy for the European decision 2002/657/EC. Proceedings of Euro FoodChem XII. Strategies for Safe Food. 2003:9194.
47. Guidance for Industry. Bioanalytical Method Validation. Rockville, MD: U.S. Food and Drug Administration; 2001.
48. Eurachem Working Group. The Eurachem Guide. The Fitness for Purpose of Analytical Methods. A Laboratory Guide to Method Validation and Related Topics. Edition 1.0. Middlesex, UK: Teddington; 1998.
49. The Commission of the European Communities. Commission Decision (2002/657/EC) implementing Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. Off J Eur Union. 2002;L221:8-36.
50. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75:3019-3030.
51. Graham AS, Matthew JB, Jürgen OD, et al. (R)-Sila-venlafaxine: a selective noradrenaline reuptake inhibitor for the treatment of emesis. Bioorg Med Chem Lett. 2006;16:2555-2558.
52. Lajeunesse A, Gagnon C, Sauvé S. Determination of basic antidepressants and their N-desmethyl metabolites in raw sewage and wastewater using solid-phase extraction and liquid chromatography-tandem mass spec-trometry. Anal Chem. 2008;80:5325-5333.
53. Schultz MM, Furlong ET. Trace analysis of antidepressant pharmaceuticals and their select degradates in aquatic matrixes by LC/ESI/MS/MS. Anal Chem. 2008;80:1756-1762.
54. Smyth WF, Leslie JC, McClean S, et al. The characterisation of selected antidepressant drugs using electrospray ionisation with ion trap mass spectrometry and with quadrupole time-of-flight mass spectrometry and their determination by high-performance liquid chromatography/electro-spray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006;20:1637-1642.